2024 Laboratory Reimbursement Trends and What to Expect in 2025
Revenue cycle management experts weigh in on the biggest developments of 2024 and how labs can best prepare for 2025 and beyond
Keep up to date on the latest legal, compliance, and business developments affecting the lab industry, while offering analysis and insight to ensure your lab’s success.
Revenue cycle management experts weigh in on the biggest developments of 2024 and how labs can best prepare for 2025 and beyond
Recent advisory opinion offers insight on how healthcare providers may want to structure arrangements involving online directories.
Inadequate CMS oversight resulted in $888.2 million in improper payments for the highest reimbursing molecular pathology genetic tests, report says.
The proposed PFS rule also includes other changes that will affect physician, lab, and other reimbursements in 2024 and beyond.
Recently proposed rule seems too stringent to reduce the lag between FDA approval and Medicare coverage.
Centers for Medicare & Medicaid Services proposes TCET pathway to expedite Medicare Coverage of newly approved breakthrough devices.
Deciding whether to purchase or lease laboratory instrumentation involves a variety of factors.
Release of second-generation Cologuard test data and recently announced partnerships aim to position company well for the future.
Diagnostics companies that invested heavily in COVID-19 products are relying on M&A transactions to restructure and transition.
In the first half of this year, US companies have cut the second-highest total of jobs since 2009, according to a recent report.
A recent SCOTUS ruling on a healthcare fraud case could help defend labs against baseless whistleblower cases.